Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive CancerAlison M. Schram, Alexander Drilon, Kōichi Goto et al.|New England Journal of Medicine|2025Cited by 104
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumorsYonina R. Murciano‐Goroff, Joshua K. Sabari, Alexander I. Spira et al.|Cancer Research|2023Cited by 37
<i>NRG1</i> fusions in solid tumors.Brinda Gupta, Stephen V. Liu, Sharon Wu et al.|Journal of Clinical Oncology|2023Cited by 7
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 TrialAlexander Drilon, Byoung Chul Cho, D. Ross Camidge et al.|Journal of Thoracic Oncology|2024Cited by 0